Predict your next investment

Venture Capital
panoramacapital.com

See what CB Insights has to offer

Investments

86

Portfolio Exits

26

Funds

1

About Panorama Capital

Panorama Capital is a venture capital firm focused on life sciences and technology companies. Panorama Capital was founded in 2005 by: Srinivas Akkaraju M.D., Ph.D.; Christopher J. Albinson; Rodney A. Ferguson, J.D., Ph.D.; Shahan D. Soghikian; and Damion E. Wicker, M.D., along with a core team of investment professionals who worked together for many years. Together, this team has a singular focus: helping entrepreneurs build market-leading companies. Panorama invests in entrepreneurs and teams who share its values: a passion to build great companies; an unyielding focus on people and teamwork; and a commitment to integrity. Panorama's philosophy is to make that same commitment to the teams it supports, over and above its financial investment, and to take a hands-on, highly collaborative approach to investing, bringing to each portfolio company the team's extensive operating and investing experience.

Panorama Capital Headquarter Location

2440 Sand Hill Road, Suite 302

California, 94025,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Panorama Capital News

Scholar Rock : Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors - Form 8-K

Jul 26, 2022

05:03p 07/26/2022 | 05:12pm EDT Message : Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors CAMBRIDGE, Mass.-July 26, 2022- Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Dr. Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital, has been appointed to Scholar Rock's Board of Directors as an independent director. With over two decades of fundamentals-based, long term investment experience in the biotechnology sector, Dr. Akkaraju will add valuable experience and insight to Scholar Rock's Board of Directors as the company advances its late stage development pipeline and also invests in its robust discovery programs. "We are thrilled to welcome Dr. Akkaraju to Scholar Rock's Board of Directors as we continue to expand upon our diverse network of experienced biotechnology company-builders," said Nagesh Mahanthappa, Ph.D., Founding Chief Executive Officer & President of Scholar Rock. "Dr. Akkaraju's deep understanding of our scientific platform, our clinical programs and the complexities of the biotech capital markets, will be an invaluable addition to our Board as we work diligently to accelerate our highly innovative therapeutic candidate for spinal muscular atrophy through its Phase 3 clinical trial and begin planning for our first potential commercial launch." "I have always been passionate about supporting innovation that has transformative potential for patients and I am inspired by Scholar Rock's mission and data-driven approach making use of its proprietary platform to modulate growth factors in the TGFβ superfamily to achieve differentiated pharmacology with huge therapeutic potential," said Dr. Akkaraju. "I have been closely following Scholar Rock's progress over several years, and I am looking forward to partnering with the Board and the executive leadership team as we continue advancing the company's progress towards improving the current standard of care for a range of serious diseases." In 2017, Dr. Akkaraju founded Samsara BioCapital, where he currently serves as Managing General Partner. A biotech investment fund that recently invested in Scholar Rock's completed registered direct offering, Samsara is focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Prior to Samara, Dr. Akkaraju held key strategic, leadership, operational, and advisory roles at various venture capital firms focusing on the biopharmaceutical and life science industries, including Sofinnova Investment, Inc., New Leaf Venture Partners, and Panorama Capital, LLC. Prior to co-founding Panorama Capital in 2005, he served as a Partner with J.P. Morgan Partners and advised on Business and Corporate Development at Genentech, Inc. Dr. Akkaraju received his M.D. and a Ph.D. in Immunology from Stanford University and his undergraduate degrees in Biochemistry and Computer Science from Rice University. He also serves as a director of Chinook Therapeutics, Intercept Pharmaceuticals, Syros Pharmaceuticals, and Jiya Acquisition Corp. Previously, Dr. Akkaraju served as a director on the Boards of Seattle Genetics, Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., aTyr Pharma, and Amarin Corporation plc. About Scholar Rock Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn ( https://www.linkedin.com/company/scholar-rock/) . Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Scholar Rock® is a registered trademark of Scholar Rock, Inc. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, and progress and indication selection and development timing, the ability of any individual to affect the growth, strategy, and progress of Scholar Rock, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might," "could," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, Scholar Rock's ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock's nonclinical and preclinical studies and clinical trials, and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business activities, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. Scholar Rock:

Panorama Capital Investments

86 Investments

Panorama Capital has made 86 investments. Their latest investment was in NinthDecimal as part of their Unattributed VC - III on July 7, 2021.

CBI Logo

Panorama Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/13/2021

Unattributed VC - III

NinthDecimal

$1M

No

1

9/11/2020

Unattributed VC - II

NinthDecimal

$8M

No

1

8/17/2016

Series A

Alterra Home Loans

$6.56M

Yes

1

8/17/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

3/17/2016

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/13/2021

9/11/2020

8/17/2016

8/17/2016

3/17/2016

Round

Unattributed VC - III

Unattributed VC - II

Series A

Seed VC

Unattributed VC

Company

NinthDecimal

NinthDecimal

Alterra Home Loans

Subscribe to see more

Subscribe to see more

Amount

$1M

$8M

$6.56M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Panorama Capital Portfolio Exits

26 Portfolio Exits

Panorama Capital has 26 portfolio exits. Their latest portfolio exit was Zilliant on December 06, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/6/2021

Acq - Fin

$99M

1

9/10/2020

Acquired

$99M

2

10/14/2019

Acq - P2P

$99M

4

3/18/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/31/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/6/2021

9/10/2020

10/14/2019

3/18/2019

7/31/2018

Exit

Acq - Fin

Acquired

Acq - P2P

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

2

4

10

10

Panorama Capital Fund History

1 Fund History

Panorama Capital has 1 fund, including Panorama Capital I LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/28/2008

Panorama Capital I LP

Multi-Stage Venture Capital

Closed

$240M

1

Closing Date

4/28/2008

Fund

Panorama Capital I LP

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

$240M

Sources

1

Panorama Capital Team

14 Team Members

Panorama Capital has 14 team members, including current Chief Financial Officer, Audrey Vallen.

Name

Work History

Title

Status

Christopher J. Albinson

Founder

Current

Audrey Vallen

Bay Partners, Institutional Venture Partners, and PwC

Chief Financial Officer

Current

Rodney A. Ferguson

Managing Director

Current

Shahan D. Soghikian

J.P. Morgan Chase & Co.

Managing Director

Current

Damion Edwin Wicker

Managing Director

Current

Name

Christopher J. Albinson

Audrey Vallen

Rodney A. Ferguson

Shahan D. Soghikian

Damion Edwin Wicker

Work History

Bay Partners, Institutional Venture Partners, and PwC

J.P. Morgan Chase & Co.

Title

Founder

Chief Financial Officer

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.